Pyrukynd Tablet, Film Coated
Product Images NDC 71334-210

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Pyrukynd (NDC 71334-210). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Agios Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Pyrukynd 01)

FDA Label Image

Figure 1 (Pyrukynd 02)

FDA Label Image

Figure 2 (Pyrukynd 03)

FDA Label Image

Principal Display Panel (5 mg Tablet Blister Pack Carton)

This is a description of the storage and usage instructions for Pyrkind tablets by Agios Pharmaceuticals. It includes information on how to store the tablets and their recommended usage as well as instructions to keep the tablets out of reach of children. The text also contains a warning to not split, crush, chew or dissolve the tablets before swallowing. It provides contact information for further inquiries and information on the quantity contained in the product.*

FDA Label Image

Principal Display Panel (20 mg Tablet Blister Pack Carton)

This is a medication description for Pyrukind tablets, which contain 20mg mitapivat, a medicine used for treating certain blood disorders. The recommended dosage information is not available and the tablets should be kept away from children and stored in a controlled room temperature. The manufacturer of the tablets is Agios Pharmaceuticals Inc. and for any further information, one can visit their website or call the given number. The tablets are available in a four-week supply pack and caution must be taken not to use them if the seal is broken or damaged.*

FDA Label Image

Principal Display Panel (50 mg Tablet Blister Pack Carton)

FDA Label Image

Principal Display Panel (5 mg Tablet Blister Pack Carton)

This is a medication label for Pyruvate Kinase Deficiency in adults that contains information about the dosage and directions for use. The tablet should be swallowed whole and not crushed or dissolved. It is recommended to store the medication at room temperature. The drug name is Pyrukynd and the strength is 5mg.*

FDA Label Image

Principal Display Panel (20 mg/5 mg Tablet Blister Pack Carton)

This is a label for a medication called Pyruvate Kinase Deficiency Mitapivat Tablets which come in a Taper Pack of 20mg and 5mg. The label includes warnings not to use broken or damaged tablets, and not to split, crush, chew or dissolve the tablets. It also includes storage instructions and contact information for medical recommendations.*

FDA Label Image

Principal Display Panel (50 mg/20 mg Tablet Blister Pack Carton)

This appears to be a medication label for tablets called "pyrukynd" with dosages of 50mg and 20mg. The label includes information on how to take the medication, caution against breaking or damaging the tablets, and recommended storage conditions. It also advises against crushing, chewing, or dissolving the tablets. However, the label contains several errors and incomplete sentences, making it difficult to understand the complete instructions.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.